COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marla C. Dubinsky  ¹     Keith A. Betts  ²     Kenneth LaPensee  ³     Lei Yin     Devrim Eren     Wenxi Tang     Komal Gupte-Singh    
¹ Icahn School of Medicine at Mount Sinai, New York, United States
² Analysis Group, Inc., Los Angeles, United States
³ Bristol Myers Squibb Company, Princeton, United States

Session
Health economical aspect in GI disorders

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)